logo
Plus   Neg
Share
Email

Medicines360: FDA Approves Extended Duration Of Use For LILETTA

Medicines360 and Allergan plc (AGN) announced the U.S. FDA has approved Medicines360's Supplemental New Drug Application to extend the duration of use of LILETTA 52 mg for the prevention of pregnancy for up to six years. LILETTA is a hormone-releasing system placed in a woman's uterus to prevent pregnancy. Medicines360 noted that the approval marks the longest approved duration of use of any hormonal intrauterine devices.

Medicines360 received initial approval of LILETTA in 2015. Since then, Medicines360 and Allergan have continued to invest in the product. LILETTA is available at a lower cost to public health clinics enrolled in the 340B Drug Pricing Program.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT